{‘She has no expertise’: the American scientific field girds for Høeg's appointment at the Food and Drug Administration.

As the US undertakes unprecedented adjustments to its immunization guidelines, a particular individual appears in a surprising turn: Høeg, a US-based sports medicine doctor and public health researcher who initially gained attention by casting doubt on COVID-19 vaccinations during the global health crisis and has zeroed in on potential deaths following COVID-19 immunization in her short time at the US Food and Drug Administration (FDA).

Proposed Overhauls to Childhood Immunization Program

Health officials had intended to reveal sweeping revisions to the pediatric immunization program recently, bringing the US with Denmark’s national calendar, according to reports – a significant shift that would place the US at odds with many the international standard with no evidence for benefit. This reveal has been pushed back until the coming year.

Instead of the top vaccines chief, Høeg is scheduled to speak at the gathering. She was recently named interim head of the FDA’s Center for Drug Evaluation and Research (CDER), the fifth person to lead the office this year.

Consolidating Power at the FDA

This interim role may indicate a closer partnership between the drug and vaccine branches as Høeg and Dr. Prasad consolidate power at the agency – and it points to a greater focus upon dismantling long-standing immunizations at the FDA.

The new acting director has often pushed for ending specific pediatric vaccine recommendations in the US in order to be more like the Danish model, a country with universal health coverage and a number of inhabitants approximately the size of Wisconsin’s.

In her initial public appearances, she has kept her attention on vaccination policy – traditionally the responsibility of Prasad, director of the FDA’s Center for Biologics Evaluation and Research (CBER) – rather than pharmaceutical oversight.

Questions Over Expertise

The appointee has no apparent experience in medication creation, oversight or administrative roles, which has been customary for former leaders of the Center for Biologics Evaluation and Research. She has worked at the FDA as a senior adviser to the agency head and the vaccine center since earlier this year.

“She doesn’t seem to have the necessary background” for overseeing the pharmaceutical oversight division, remarked Dr. Jonathan Howard. “She lacks experience running a randomized controlled trial. She has no expertise in running a large organization. She lacks background in industry regulation.”

Past directors of CBER would “be deeply familiar with regulatory frameworks and the underlying principles of drug development”, commented a former acting FDA commissioner. “Frankly, she lacks the sort of resume that previous people who ran the center have had.”

CDER has an immense workload at the agency, she pointed out.

“Everybody just focuses on the innovative therapies, but the generic drug division approves numerous off-brand pharmaceuticals. There is also a biosimilars program, over-the-counter program and other areas, and each of these need to be supervised,” she said. “The responsibility you neglect, that is the part that I always told people is going to bite you.”

Furthermore, a major leadership aspect to the role, which manages more than 5,000 employees. “It’s a massive management job, if you perform it correctly,” Woodcock said.

Response and Controversial Initiatives

When asked about concerns about Dr. Høeg's qualifications and whether this assignment indicates more teamwork among agency officials on immunizations, a spokesperson responded that the “inquiries rely on incorrect premises”.

“Her resume is consistent with the duties of her position,” the spokesperson explained, citing the months Høeg spent guiding the FDA commissioner on “pharmaceutical safety and oversight research, including computational safety modeling and immunization monitoring”.

As acting director, Høeg assumes responsibility for the agency head's recently launched priority voucher program, a contentious rapid medication authorization process that allegedly concerned her predecessors. “By what process are these therapies being selected for this voucher program? Who makes the decisions?” Howard said. “There’s a lot of secrecy going on at the FDA right now.”

In general, he stated, “the agency appears to be shifting towards more relaxed rules of all drugs, except for vaccines.”

Public History on Vaccines

With vaccines, Dr. Høeg has a more documented, if concerning, past, some experts said. She published a analysis using unverified public submissions to estimate the incidence of heart inflammation after Covid vaccination. She consulted for the state of Florida chief medical officer Joseph Ladapo, who was said to have changed statistics to suggest Covid vaccinations are more dangerous than they are.

Part of her “policy goals” for the current federal leadership included revising regulations for novel immunizations and discontinuing “non-essential” vaccines, she stated post-election on a podcast. At the agency, Dr. Høeg has reportedly suggested barring adolescent males from receiving Covid vaccinations.

“She’s an thorough dogmatist who starts off with her conclusions and reverse-engineers to fit the data in a highly misleading, untruthful fashion,” Dr. Howard argued.

Gaining Influence and a “Campaign of Retribution”

Høeg joined other dissenters, {like|